Aurélie Candi

Aurélie Candi

Auto-generated profile, based on publicly available information

Aurélie Candi

CISTIM Leuven vzw, Leuven, Belgium

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2023 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
HHHanne Hillen
Hanne Hillen
ACAurélie Candi
Aurélie Candi
BVBart Vanderhoydonck
Bart Vanderhoydonck
WKWeronika Kowalczyk
Weronika Kowalczyk
LSLeticia Sansores-Garcia
Leticia Sansores-Garcia
GHGeorg Halder
Georg Halder
The Hippo pathway and its downstream effectors, the YAP and TAZ transcriptional coactivators, are deregulated in multiple different types of human cancer and are required for cancer cell phenotypes in vitro and in vivo, while largely dispensable for tissue homeostasis in adult mice. YAP/TAZ and their main partner transcription factors, the TEAD1–4 factors, are therefore promising anticancer targets. Because of frequent YAP/TAZ hyperactivation caused by mutations in the Hippo pathway components NF2 and LATS2, mesothelioma is one of the prime cancer types predicted to be responsive to YAP/TAZ-TEAD inhibitor treatment. Mesothelioma is a devastating disease for which currently no effective treatment options exist. Here, we describe a novel covalent YAP/TAZ-TEAD inhibitor, SWTX-143, that binds to the palmitoylation pocket of all four TEAD isoforms. SWTX-143 caused irreversible and specific inhibition of the transcriptional activity of YAP/TAZ-TEAD in Hippo-mutant tumor cell lines. More importantly, YAP/TAZ-TEAD inhibitor treatment caused strong mesothelioma regression in subcutaneous xenograft models with human cells and in an orthotopic mesothelioma mouse model. Finally, SWTX-143 also selectively impaired the growth of NF2-mutant kidney cancer cell lines, suggesting that the sensitivity of mesothelioma models to these YAP/TAZ-TEAD inhibitors can be extended to other tumor types with aberrations in Hippo signaling. In brief, we describe a novel and specific YAP/TAZ-TEAD inhibitor that has potential to treat multiple Hippo-mutant solid tumor types.

29 October 2017 in Journal of Ophthalmology
Verified
Journal Article
Open access
PDF file
BJBart Jonckx
Bart Jonckx
MPMichael Porcu
Michael Porcu
ACAurelie Candi
Aurelie Candi
IEIsabelle Etienne
Isabelle Etienne
PBPhilippe Barbeaux
Philippe Barbeaux
JFJean H. M. Feyen
Jean H. M. Feyen
Ocriplasmin (Jetrea®) is a recombinant protease used to treat vitreomacular traction. To gain insight into vitreoretinal observations reported after ocriplasmin treatment, we have developed anin vivoporcine ocriplasmin-induced posterior vitreous detachment (PVD) model in which we investigated vitreoretinal tissues by optical coherence tomography, histology, and cytokine profiling. Eight weeks postinjection, ocriplasmin yielded PVD in 82% of eyes. Subretinal fluid (85%) and vitreous hyperreflective spots (45%) were resolved by week 3. Histological analysis of extracellular matrix (ECM) proteins such as laminin, fibronectin, and collagen IV indicated no retinal ocriplasmin-induced ECM distribution changes. Retinal morphology was unaffected in all eyes. Cytokine profiles of ocriplasmin-treated eyes were not different from vehicle. In cell-based electrical resistance assays, blood-retinal barrier permeability was altered by ocriplasmin concentrations of 6 μg/mL and higher, with all effects being nontoxic, cell-type specific, and reversible. Ocriplasmin was actively taken up by RPE and Müller cells, and our data suggest both lysosomal and transcellular clearance routes for ocriplasmin. In conclusion, transient hyperreflective spots and fluid in a porcine ocriplasmin-induced PVD model did not correlate with retinal ECM rearrangement nor inflammation. Reversiblein vitroeffects on blood-retinal barrier permeability provide grounds for a hypothesis on the mechanisms behind transient subretinal fluid observed in ocriplasmin-treated patients.

8 May 2025 in Cell Death & Differentiation
Verified
Journal Article
Closed access
PDF file
SJSven Jonckheere
Sven Jonckheere
JTJoachim Taminau
Joachim Taminau
JAJamie Adams
Jamie Adams
JHJef Haerinck
Jef Haerinck
JCJordy De Coninck
Jordy De Coninck
GBGeert Berx
Geert Berx


3 January 2024
Verified
Other
Open access
PDF file
HHHanne Hillen
Hanne Hillen
ACAurélie Candi
Aurélie Candi
BVBart Vanderhoydonck
Bart Vanderhoydonck
WKWeronika Kowalczyk
Weronika Kowalczyk
LSLeticia Sansores-Garcia
Leticia Sansores-Garcia
GHGeorg Halder
Georg Halder
Figure S2 shows A) Heatmap showing YAP signature genes in vehicle and SWTX-143-treated kidney cancer cell line. B) Gene Set Enrichment Analysis of the YAP signature.

3 January 2024
Verified
Other
Open access
PDF file
HHHanne Hillen
Hanne Hillen
ACAurélie Candi
Aurélie Candi
BVBart Vanderhoydonck
Bart Vanderhoydonck
WKWeronika Kowalczyk
Weronika Kowalczyk
LSLeticia Sansores-Garcia
Leticia Sansores-Garcia
GHGeorg Halder
Georg Halder
Figure S3 shows Heatmap of differential pathway analysis comparing the tumors of vehicle and SWTX-143-treated mice.